Other languages TFF Pharmaceuticals, Inc.

Equities

TFFP

US87241J2033

Market Closed - Nasdaq Other stock markets 02:00:00 11/05/2024 am IST			5-day change	1st Jan Change
1.95 ^USD	-10.55%		-3.94%	-72.22%

30/04	TFF Pharmaceuticals Prices $4.8 Million Public Offering; Shares Down Pre-Bell	MT
29/04	TFF Pharmaceuticals, Inc. Makes Available Phase 2 Data from Tacrolimus Inhalation Powder for Prevention of Lung Transplant Rejection Presented at Recent ISHLT Annual Meeting	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

TFF Pharmaceuticals Prices $4.8 Million Public Offering; Shares Down Pre-Bell	30/04
TFF Pharmaceuticals, Inc. Makes Available Phase 2 Data from Tacrolimus Inhalation Powder for Prevention of Lung Transplant Rejection Presented at Recent ISHLT Annual Meeting	29/04
TFF Pharmaceuticals, Inc. Announces Additional Positive Data from the Tacrolimus Inhalation Powder (TFF Tac) Phase 2 Trial Following Oral Presentation At the Ishlt 44Th Annual Late-Breaking Clinical Science Abstract Sessions	15/04
TFF Pharmaceuticals Files Equities Shelf	08/04
TFF Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	29/03
TFF Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/03
TFF Pharmaceuticals, Inc. Announces Updated Data from the Tacrolimus Inhalation Powder (TFF TAC) and Voriconazole Inhalation Powder (Tff VORI) Clinical Programs	28/03
TFF Pharmaceuticals Sells Stock in Registered Direct Offering	20/03
TFF Pharmaceuticals, Inc. Announces Update on Clinical Programs	20/03
TFF Pharmaceuticals, Inc. to Present Data from Phase 2 Trial of Voriconazole Inhalation Powder for the Treatment of Invasive Pulmonary Aspergillosis At the 11Th Advances Against Aspergillosis & Mucormycosis & Mucromycosis Conference	24/01
TFF Pharmaceuticals, Inc. Announces Positive Initial Data from Ongoing Phase 2 Trials of TFF VORI and TFF TAC	19/12
TFF Pharmaceuticals, Inc. Appoints Thomas B. King to Board of Directors	14/12
TFF Pharmaceuticals, Inc. Appoints Michael Patane to its Board of Directors and Compensation Committee	30/11
TFF Pharmaceuticals, Inc. Appoints Catherine Lee to its Board of Directors and Nominating & Corporate Governance Committee	30/11
TFF Pharmaceuticals Files $100 Million Mixed Shelf	22/11
TFF Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	15/11
Aaron Fletcher Advises TFF Pharmaceuticals, Inc. of His Decision Not to Stand for Reelection to the Board	19/23/19
Insider Buy: Tff Pharmaceuticals	15/23/15
TFF Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	15/23/15
Uniphar Durbin Ireland Limited and TFF Pharmaceuticals, Inc. Announce Opening of Expanded Access Program for Voriconazole Inhalation Powder for Treatment of Pulmonary Aspergillosis and Other Voriconazole Responsive Fungal Pulmonary Infections	31/23/31

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages TFF Pharmaceuticals, Inc.

Equities

TFFP

US87241J2033

Other languages

Filters